
- /
- Supported exchanges
- / US
- / DCTH.NASDAQ
Delcath Systems Inc (DCTH NASDAQ) stock market data APIs
Delcath Systems Inc Financial Data Overview
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Delcath Systems Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Delcath Systems Inc data using free add-ons & libraries
Get Delcath Systems Inc Fundamental Data
Delcath Systems Inc Fundamental data includes:
- Net Revenue: 70 240 K
- EBITDA: 5 178 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: 0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Delcath Systems Inc News

Invesco Backs Delcath Systems (DCTH) on Expansion Potential
Delcath Systems, Inc. (NASDAQ:DCTH) is among the fastest growing small cap stocks to buy. Invesco Ltd. has expanded its position in Delcath Systems, Inc. (NASDAQ:DCTH) through the acquisition of 399,3...


H.C. Wainwright Remains Bullish on Delcath Systems (DCTH)
Delcath Systems, Inc. (NASDAQ:DCTH) is one of the best medical device stocks to buy according to analysts. On August 6, H.C. Wainwright analyst Swayampakula Ramakanth maintained a bullish stance on De...

Delcath outlines 175% projected HEPZATO volume growth and targets up to 28 operational centers by year-end 2025 amid expanding clinical pipeline
Earnings Call Insights: Delcath Systems (DCTH) Q2 2025 MANAGEMENT VIEW * Gerard J. Michel, CEO, highlighted, "Quarterly revenue reached $24.2 million, an increase of over 20% compared to the first...

Delcath Systems GAAP EPS of $0.07 beats by $0.05, revenue of $24.2M beats by $1.18M
* Delcath Systems press release [https://seekingalpha.com/pr/20190883-delcath-systems-reports-second-quarter-2025-results-and-business-highlights] (NASDAQ:DCTH [https://seekingalpha.com/symbol/DCTH]...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.